<code id='CA7ED55895'></code><style id='CA7ED55895'></style>
    • <acronym id='CA7ED55895'></acronym>
      <center id='CA7ED55895'><center id='CA7ED55895'><tfoot id='CA7ED55895'></tfoot></center><abbr id='CA7ED55895'><dir id='CA7ED55895'><tfoot id='CA7ED55895'></tfoot><noframes id='CA7ED55895'>

    • <optgroup id='CA7ED55895'><strike id='CA7ED55895'><sup id='CA7ED55895'></sup></strike><code id='CA7ED55895'></code></optgroup>
        1. <b id='CA7ED55895'><label id='CA7ED55895'><select id='CA7ED55895'><dt id='CA7ED55895'><span id='CA7ED55895'></span></dt></select></label></b><u id='CA7ED55895'></u>
          <i id='CA7ED55895'><strike id='CA7ED55895'><tt id='CA7ED55895'><pre id='CA7ED55895'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:763
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Science's Marcia McNutt, trailblazer for women, encounters sexism scandal
          Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

          MarciaMcNutthasbeentappedtoleadtheNationalAcademyofSciences.DrewAngererforSTATThefirstwomantappedtol

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          The effects of a landmark ruling on DNA ownership are becoming clearer

          AdobeToday,ifyouwanttoknowwhatscaryfamilyhealthsecretslayburiedinyourDNAorgetscreenedforalurkingcanc